|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 4 (February 15), 2000:
pp. 1342-1349
IMMUNOBIOLOGY
Stimulation of cytotoxic T cells against idiotype immunoglobulin
of malignant lymphoma with protein-pulsed or idiotype-transduced
dendritic cells
Frank Osterroth,
Annette Garbe,
Paul Fisch, and
Hendrik Veelken
From the Departments of Hematology/Oncology and Pathology, Freiburg
University Medical Center; the Department of Biology, Freiburg
University; and Cellgenix GmbH, Freiburg, Germany.
 |
Abstract |
Because of their hypervariable regions and somatic mutations, the
antigen receptor molecules of lymphomas (idiotypes) are tumor-specific antigens and attractive targets for antilymphoma immunotherapy. For the optimal induction of human idiotype-specific cytotoxic T cells (CTL), idiotype was presented to
CD8+ peripheral blood mononuclear cells by
monocyte-derived autologous dendritic cells (DC) after the endocytosis
of idiotype protein or by idiotype-expressing DC. Recombinant
idiotype was obtained as a functionally folded Fab fragment by
periplasmic expression in Escherichia coli. Idiotype-expressing
DC were generated by transduction with recombinant Semliki forest virus
vectors encompassing heavy- or light-chain idiotype genes.
Autologous lymphoblastoid cell lines stably transfected with
Epstein-Barr virus-based idiotype expression vectors were used as
target cells to detect idiotype-specific lysis. CTL stimulated with
idiotype-loaded DC showed strong specific, CD8-mediated, and major
histocompatibility complex (MHC) class I-restricted cytotoxicity
against autologous heavy- and light-chain idiotype. In contrast,
stimulation with idiotype-transduced DC resulted in only moderate
natural killer cell activity. These data confirm the existence of
idiotype-specific CTL in patients with lymphoma, define a "good
manufacturing practice"-compatible protocol for the generation of
these cells without the requirement of viable lymphoma cells, and favor
the processing of exogenous antigen over DC transduction for the
induction of MHC I-restricted CTL against idiotypes with unknown antigenicity.
(Blood. 2000;95:1342-1349)
© 2000 by The American Society of Hematology.
 |
Introduction |
During the past decade, dendritic cells (DC) have been
identified as the most potent antigen-presenting cells of the immune system.1,2 Their particular efficiency to induce specific immune responses is based on several specialized functions. Immature DC, also referred to as Langerhans-type DC (LC), have a high capacity for antigen uptake and processing.3,4 Processed
oligopeptides of protein antigens are efficiently loaded onto major
histocompatibility complex (MHC) class II molecules through an
endosomal pathway and onto MHC class I molecules by a less understood
mechanism known as cross-presentation.2,5 After antigen
uptake, DC migrate to regional lymph nodes and undergo terminal
maturation. Consequently, they acquire an outstanding capacity to
induce T cells specific for the antigens presented by DC. The
expression of human leukocyte antigen (HLA) molecules and
costimulatory molecules on the surface of DC is up-regulated, and
T-cell stimulatory cytokines, predominantly IL-12, are
released.1,2
After their immunostimulatory potential became recognized, DC have
attracted interest as a therapeutic tool to activate the immune system
against antigens that usually fail to elicit sufficiently strong
immunity for protection of the host organism. This applies in
particular to tumor-associated antigens (TAA), to which potentially reactive T cells may be infrequent6 or may be in an anergic state.7,8 Laboratory techniques to obtain DC in sufficient quality and quantity from monocytes9,10 or hematopoietic
progenitor cells11,12 have been developed and have
facilitated clinical trials for tumor vaccination. Indeed, objective
tumor regression has been reported after DC-based immunization against
the immunoglobulin expressed by malignant lymphomas13 and
against melanoma-associated antigens.14
Although it is widely accepted that TAA-specific cytotoxic T cells
(CTL) are the most important immune effector cells against malignant
melanoma,15,16 the main effector mechanism against lymphoma
cells has been more difficult to identify. Hypervariable sequences and
somatic mutations of the lymphoma immunoglobulin variable regions
result in individual tumor-specific antigens. Therefore, the antigen
receptor of a given lymphoma, also referred to as an idiotype,
represents a likely target structure for antitumor immunity.
Tailor-made anti-idiotypic monoclonal antibodies alone can induce tumor
remissions in vivo.17 In addition, lymphoma-specific CTL
have been detected in patients.18,19 After the
anti-idiotype vaccination of patients with malignant lymphoma,
humoral and T-cell responses have been described.20-22 In
animal models, the main effector mechanism appears to vary depending on
the vaccination protocol and on the tumor model used.23-26
As a prerequiste to define further the role of idiotype-specific
CTL in antilymphoma immunity, we performed a series of experiments to
determine the efficiency of DC in inducing human idiotype-specific T cells in vitro. In addition to providing further evidence for the
existence of these effector cells in patients pretreated for lymphoma,
we sought to define optimal conditions for the induction of
idiotype-specific CTL and to develop a protocol for the generation of these cells for adoptive transfer treatment strategies that could
meet "good manufacturing practice" (GMP) criteria.
 |
Methods |
Patient samples
Frozen lysates from nonsterile, single-cell suspensions prepared
from biopsy specimens with histologically and immunophenotypically confirmed infiltrations of malignant lymphoma cells were obtained from
the diagnostic immunophenotyping laboratory of our institution and
stored at 70°C. Patients gave their informed consent for the
use of their cryopreserved tumor cells and for the acquisition of
additional heparinized blood samples from routinely performed phlebotomies during complete clinical remission. The experiments were
approved by the local ethics committee.
Patient 1 was a 43-year-old man diagnosed with a nonsecreting
polymorphic immunocytoma, stage IIIB. The surface immunoglobulin of the
tumor cells was IgM . The patient was treated successfully by
polychemotherapy, including high-dose BEAM chemotherapy with autologous
peripheral stem cell transplantation. He was in clinical complete
remission for 11 months when the first peripheral blood samples were
taken. His HLA type was A 0201, B 07, C 07 as determined by DNA typing.
Patient 2 was a 57-year-old woman with IgM -positive follicular
lymphoma, stage IIA, involving the cervical and submandibular lymph
nodes. She underwent extended-field radiotherapy (40 Gy) with curative
intent and was in complete remission for 6 months when the first blood
samples were obtained. Her HLA type was A 0205/31, B 40/49, C 02/07.
Production of lymphoma-derived idiotype protein as recombinant
Fab fragment
Total RNA was isolated from lymphoma cells by centrifugation-driven
chromatography through a silica matrix (RNeasy columns; Qiagen, Hilden,
Germany) and converted to cDNA with RNaseH-deficient reverse
transcriptase (Gibco BRL, Paisley, UK) and an oligo-dT primer. cDNA of
more than 400 bp was purified by spun-driven chromatography through
Sepharose CL-4B (Pharmacia, Uppsala, Sweden) and tailed at the 3'
end with dGTP by terminal transferase (Boehringer Mannheim, Mannheim,
Germany). Immunoglobulin transcripts were amplified by polymerase chain
reaction (PCR) with recombinant Taq polymerase (Perkin Elmer,
Norwalk, CT) using nested µ or constant region-specific primers
and an oligo-dC-containing anchor primer.27 PCR products were cloned into a TA-PCR cloning vector (Invitrogen, Carlsbad, CA) and
sequenced with an automated DNA sequencer (model 373; Applied
Biosystems, Foster City, CA).
Clonally rearranged, bona fide lymphoma-derived heavy- and light-chain
variable region sequences were cloned into the dicistronic periplasmic
expression pFAB. 27 after reamplification with primers
adding the appropriate restriction sites and Vent polymerase (New England Biolabs, Beverly, MA). Escherichia coli JM83 were transformed with the resultant individual Fab expression vectors, grown
to an OD550nm of 0.5, and induced with 0.2 mg/L
anhydrotetracycline (Fisher Scientific, Nidderau, Germany) for 3 hours.
The periplasmic cell fraction was isolated by lysis with 100 mmol/L Tris-HCl (pH 8)/0.5 mol/L sucrose/1 mmol/L EDTA,
followed by centrifugation for 10 minutes at 4000g. After
dialysis overnight against 0.5 mol/L betaine monohydrate (Fluka,
Deisenhofen, Germany)/50 mmol/L Na phosphate (pH 7.5), recombinant Fab
fragments were purified from these periplasmic cell fractions by
conventional affinity chromatography on a Zn2+ column
(chelating Sepharose fast flow; Pharmacia).28,29 The purity
and integrity of the Fab fragments were assessed by standard 12%
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and silver staining. Endotoxin contamination of purified recombinant
proteins was measured with a limulus amebocyte assay (BioWhittaker,
Walkersville, MD).
Generation of idiotype-expressing lymphoblastoid cell lines
Peripheral blood mononuclear cells (107; PBMC) were
resuspended in 2 mL Epstein-Barr virus (EBV)-containing supernatant
(provided by Fisch P). After a 2-hour incubation at 37°C, 4 mL RPMI
1640 supplemented with 10% fetal calf serum (PAA Laboratories, Linz, Austria), 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, MEM vitamins
1:200, MEM nonessential amino acids 1:100, 0.1 µmol/L 2-mercaptoethanol, 50 U/mL penicillin, 50 µg/mL streptomycin (all Gibco BRL), and 1 µg/mL cyclosporin A (Novartis, Basel, Switzerland) were added. Fresh medium without cyclosporine was added once a week
until outgrowth of EBV-transformed permanent cell lines occurred.
To obtain EBV-replicon-based idiotype expression vectors, individual
clonally rearranged IgL genes and heavy-chain Fd segments (ie, the
heavy-chain variable region with the first constant domain) were
amplified from the respective pFab. clones with Vent
polymerase. In addition to sequences complementary to the cDNA, the
5' (forward) primers contained an SfiI restriction site,
a Kozak consensus sequence, and an ATG start codon (Table
1), whereas the 3' (reverse) primers
incorporated the necessary codons for a hexahistidine tag, followed by
2 stop codons and a BamHI site (Table 1). The PCR products were
inserted into the SfiI/BamHI sites of pCEP4 (Invitrogen). With an electric discharge of 250 V and 960 µF in 0.4-cm cuvettes (Bio-Rad, Hercules, CA), 2 × 107
vigorously proliferating lymphoblastoid cell line (LCL) cells were
electroporated with 20 µg pCEP4 vector. Successfully transfected cells were selected with 50 µg/mL hygromycin (Boehringer Mannheim) for 1 week and with 100 µg/mL thereafter.
Generation of human monocyte-derived dendritic cells
Fresh PBMC were prepared by Ficoll density centrifugation, suspended
in RPMI/0.5% human serum albumin (HSA fraction V; Calbiochem, La
Jolla, CA), and allowed to adhere to tissue culture flasks for 2 hours.
Nonadherent cells were removed by 3 × washing with PBS.
Adherent cells were differentiated into Langerhans-type cells (LC) in
serum-free monocyte medium (Cellgenix, Freiburg, Germany) supplemented
with 100 ng/mL granulocyte-macrophage colony-stimulating factor
(Novartis), 50 ng/mL IL-4, and 5 ng/mL transforming growth factor- 1
(both Genzyme, Cambridge, MA) for 6 days (Garbe A et al, manuscript
submitted for publication). Final differentiation to mature DC was
induced by the addition of 100 ng/mL lipopolysaccharide (LPS; Pyroquant
Diagnostik, Walldorf, Germany). Twenty-four hours later, the cell
population was used for stimulation of CTL (see below). Flow cytometry
analyses of LC and DC were performed with antibodies specific for CD1a,
CD14, and CD86 (Becton Dickinson, Mountain View, CA).
Generation and analysis of protein-loaded DC
For loading of DC with idiotype protein, 1 mg/mL solutions of
recombinant Fab fragment were denatured by heating to 80°C in a
microwave oven. This material was added to immature DC at a concentration of 50 µg/mL on day 5 of culture.
To analyze the uptake of recombinant Fab fragments by immature DC, 10 µL fluorescent dye FLUOS (Boehringer Mannheim) was incubated with 660 µg recombinant Fab fragment for 2 hours at room temperature. The
protein was purified from unbound chromophore by gel filtration through
Sephadex G-25 (Pharmacia). Photometric analysis allowed calculation of
the ratio of fluorescein molecules per protein by the formula 3.053 × OD495nm/OD280nm 0.255 × OD495nm. In typical experiments, the FLUOS/protein ratio
was approximately 15:1.
Six hours after the addition of FLUOS-labeled denatured Fab protein to
LC, 105 cells per spot were pipetted onto a
polylysine-coated, 12-spot glass slide and allowed to adhere for 30 minutes at 4°C. After fixation with 3% paraformaldehyde, cells
were analyzed by confocal laser microscopy (LSM 410 Invert microscope;
Zeiss, Oberkochen, Germany).
Construction of individual Semliki forest virus idiotype expression
vectors and generation of idiotype-transduced DC
Plasmids pSFV1, pSFVhelper1, and the cell line BHK-2130
were kindly supplied by P. Fisch. The variable light chain gene of
patient 1 was reamplified from the respective pFab. vector with
primers CEP.1Lfor and CEP.1Lrev (Table 1). The resultant PCR product
was digested with BglII and BamHI and inserted into the
singular BamHI site of pSFV1. A pSFV1-subclone with the insert in correct orientation was designated pSFV.1H. The coding region of
pSFV.1H could then be replaced with the Fd or IgL genes from the
individual pCEP expression constructs (see above) through SfiI
and BamHI.
For the production of infectious Semliki forest virus (SFV) vector
particles, idiotype sequence-carrying pSFV plasmids and plasmid
pSFVhelper1 were linearized with SpeI. Approximately
1 µg linearized plasmid was transcribed in vitro with 30 U SP6 RNA polymerase (Boehringer Mannheim) in the presence of 1 mmol/L
dithiothreitol, 1 mmol/L capping analogue m7G(5')ppp(5')G (Gibco
BRL), 1 mmol/L rNTP, and 60 U RNasin (Promega, Madison, WI) in a total
of 50 µL SP6 buffer (Boehringer Mannheim) for 2 hours at 37°C.
The packaging cell line BHK-21 was grown in DMEM with 5% FCS (PAA
Laboratories), 1:50 tryptose phosphate, 1 mmol/L L-glutamine, 50 U/mL
penicillin, and 50 µg/mL streptomycin (all Gibco BRL). When the
culture reached 90% confluence, the cells were harvested by
trypsinization and resuspended at a concentration of 107/mL
in PBS, and 0.8 mL cell suspension was mixed with 10 µg transcript of
a pSFV idiotype construct and 10 µg pSFVhelper1 transcript. After a
5-minute incubation on ice, the cells were electroporated with a double
discharge of 850 V and 960 µF in a 0.4 cm cuvette and thereafter
recultured in 10 mL medium. The supernatant was harvested after 36 hours and cryopreserved at 70°C until it was used for transduction.
After terminal differentiation of DC by LPS, cells were washed twice
with PBS and resuspended in 1:10 diluted infectious BHK-21 supernatants
for 1 hour at 37°C. Immediately afterward, cells were used for the
stimulation of PBMC or analyzed by Western blot for the expression of
idiotype protein.
Western blot analysis for expression of recombinant idiotype
5 × 106 SFV-transduced DC or
5 × 107 pCEP4-transfected LCL were harvested and
lysed in 100 µL 1% (vol/vol) Nonidet P40 in 50 mmol/L Tris-HCl (pH
7.6)/150 mmol/L NaCl/2 mmol/L EDTA. After a short centrifugation to
separate particulate material, 15 µL lysate was
electrophoresed by 12% SDS-PAGE under reducing conditions. Protein was
transferred to a polyvinylidene difluoride membrane (Hybond-P; Amersham
Buchler, Braunschweig, Germany) by electroblotting with 40 mA for 90 minutes (Transblot semidry; Bio-Rad). The membrane was blocked with 5%
milk powder in PBS/0.1% Tween 20 (blocking buffer) for 1 hour at room
temperature. The primary antibody incubation was performed with a mouse
anti-His (C-terminal) horseradish peroxidase-conjugated antibody
(Invitrogen) diluted 1:2500 in blocking buffer. After 2 washes with
0.1% Tween 20 in PBS, the membrane was incubated with a sheep
antimouse IgG-alkaline phosphatase conjugate (Amersham) 1:4000 in
blocking buffer for 1 hour. After 3 washes with 0.1% Tween 20 in PBS
and 1 wash with PBS, specific binding was detected with the
chemiluminescence Western blot detection system (Amersham) following
the instructions of the manufacturer.
Isolation of CD8+ PBMC and stimulation of CTL with DC
Using Ficoll density centrifugation, we isolated PBMC from
heparinized blood samples. CD8+ cells were purified by
depletion of CD4+, CD11b+, CD16+,
CD19+, CD36+, and CD56+ cells with
hapten-coupled antibodies against these antigens. Antibody-loaded cells
were removed with a secondary hapten-specific antibody coupled to
magnetic microbeads (MACS CD8+ T-cell isolation kit;
Miltenyi Biotech, Bergisch Gladbach, Germany).
The culture medium for T-cell stimulation consisted of RPMI
supplemented with 2 mmol/L L-glutamine, 0.55 mmol/L L-arginin, 0.24 mmol/L L-asparagine, 1 mmol/L sodium pyruvate, MEM vitamins 1:200,
MEM nonessential amino acids 1:100, 0.1 µmol/L
2-mercaptoethanol, 50 U/mL penicillin, 50 µg/mL streptomycin (all
Gibco BRL), and 5% (vol/vol) autologous human plasma. In round-bottom
microtiter wells, 5 × 104 CD8+ PBMC
were stimulated with 2 × 104 mature DC in 210 µL
medium supplemented with 1000 U/mL IL-6 and 10 ng/mL IL-12 (both
Boehringer Mannheim). T cells were pooled and restimulated with DC at
the same cell ratio at weekly intervals. After restimulations, cells
were cultured in medium supplemented with 20 U/mL IL-2 and 5 ng/mL IL-7
(both Boehringer Mannheim).31 During the entire stimulation
period, 70 µL respective culture medium was renewed every 2 to 4 days.
Detection of cytotoxic activity
To obtain appropriate target cells, 106 LCL or K562
cells were incubated with 10 to 40 µl
Na251CrO4 (Amersham) for 1 hour at
37°C. After 2 washes with RPMI, 2000 target cells were plated per
well into V-bottom microtiter plates. With the exception of blocking
experiments with antibodies, experiments with LCL as target cells were
performed as cold-target inhibition assays by adding 105
unlabeled K562 per well to exclude natural killer (NK) activity. Effector cells were added at effector-to-target ratios of 50:1, 10:1,
and 2:1 in duplicate or triplicate. For maximal lysis, 0.15% Triton-X
in medium was added. After a 4-hour incubation at 37°C, 50 µL
supernatant was counted in a scintillation counter (Lumaplate; Canberra-Packard, Dreiech, Germany). Specific lysis was calculated by
the formula (specific release spontaneous release)/(maximum release spontaneous release).
Blocking experiments were performed with effector cells preincubated
for 1 hour at 37°C with antibodies against CD3 (OKT-3; Novartis),
CD4, or CD8 (both Biotrend, Cologne, Germany). In the case of
antibodies against HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, and HLA-DQ (all
Biotrend), the target cells were incubated under otherwise identical
conditions. The concentration of all antibodies was 100 µg/mL during
the following lysis reaction. Antibody-blocking experiments were
performed without the addition of cold K562 target cells.
 |
Results |
Preparation of idiotype-presenting autologous dendritic cells from
patients with malignant lymphoma
Clonally rearranged immunoglobulin genes from patients 1 and 2 were
amplified from frozen lymphoma biopsies by anchored PCR, inserted into
a TA cloning vector, and sequenced. Consensus sequences for the
variable segments of the heavy- and light-chain genes of both patients
are given in Table 2.
After reamplification to add the appropriate restriction enzymes for
subcloning, the variable regions were inserted into the dicistronic
prokaryotic expression vector pFab. . This vector carries a single
tetracycline-inducible expression cassette for Fd and IgL genes with
specialized bacterial leader sequences exporting the polypeptides into
the periplasmic space.28 Because of the special cellular
milieu in the bacterial periplasma, IgL and Fd chains assume correct
conformation and are assembled into functionally folded Fab fragments,
including the interpeptide disulfide bond.28 Addition of a
hexahistidine tag at the C terminus of the Fd fragment allows
purification of the recombinant Fab fragment by metal affinity chromatography.29 This rapid and convenient
expression system permitted the production of virtually pure
idiotype protein in both patients (Figure
1). The protein concentration after
purification was adjusted to 1 mg/mL, and determination of the
residual endotoxin content demonstrated less than 0.2 U endotoxin/µg
protein.

View larger version (59K):
[in this window]
[in a new window]
| Fig 1.
SDS-PAGE analysis of recombinant, lymphoma-derived Fab
fragments.
Immunoglobulin transcripts from lymphoma biopsies of both patients were
amplified by PCR, sequenced, and inserted into pFab. . Recombinant
Fab fragments were expressed from pFab. vectors in E. coli. Periplasmic fractions of induced bacteria were prepared and
purified by affinity chromatography. The resultant protein eluate was
analyzed by standard 12% SDS-PAGE under reducing and nonreducing
conditions. Protein bands were visualized by silver staining. The Fd
and IgL chains of patient 2 had almost identical migration properties
under reducing conditions. Even when the gel was run with 6 mol/L urea,
the separation of the bands could not be improved (not shown). SM,
high-molecular weight marker.
|
|
Monocytes enriched from peripheral blood by adhesion to tissue
culture flasks were differentiated in vitro to immature DC in
serum-free medium supplemented with IL-4, granulocyte-macrophage colony-stimulating factor, and transforming growth factor- 1 for 6 days. One day before the induction of maturation with LPS, recombinant Fab fragments were added to the culture at a final concentration of 50 µg/mL. To analyze the uptake of recombinant idiotype by DC, an
aliquot of the cells was incubated with FLUOS-labeled Fab fragment for
6 hours under otherwise identical conditions. These cells were analyzed
by confocal microscopy to assess the location of fluorescence within
the cells. In cells with DC morphology, high fluorescence was
detected in rounded compartments with shape and location typical for
endosomes (Figure 2). The immunophenotype of DC was routinely verified by flow cytometry. More than 80% of cells
recovered from day 7 cultures expressed CD1a and CD86 and stained
negative for CD14, thus exhibiting the phenotype of mature DC since the
down-regulation of CD1a proceeded slowly after the induction of
maturation (data not shown).

View larger version (117K):
[in this window]
[in a new window]
| Fig 2.
Uptake of fluorescein-labeled recombinant Fab fragments
by monocyte-derived dendritic cells.
Fluorescence-labeled recombinant Fab fragment was added to
monocyte-derived LC at a concentration of 660 µg/mL immediately
before terminal differentiation to DC with LPS. After DC
differentiation, protein-loaded cells were pipetted onto adhesion
slides and fixed with 3% paraformaldehyde. The location of
fluorescence within the cells was assessed by confocal microscopy. In
cells with DC morphology, bright fluorescence was present in cellular
subcompartments with the typical shapes and localization of endosomes.
|
|
To generate idiotype-expressing antigen-presenting cells,
terminally differentiated DC were incubated with infectious
supernatants of idiotype SFV vector-producing BHK-21 cells. To verify
the efficient transduction of DC with SFV vectors, transduced DC were
harvested 24 hours after exposure to the vector supernatant and were
analyzed by Western blot. Blotting with an anti-His-tag antibody
permitted detection of recombinant IgL and Fd chains in DC lysates
because PCR-mediated subcloning (Table 1) introduced hexahistidine tags into all IgL and Fd inserts of the SFV vectors (Figure
3). Strong signals of the expected
molecular weights were observed in all transduced DC lysates, even when
the vector supernatant was diluted 100-fold. The intensity of the
signal indicated very efficient transduction of DC by SFV vectors,
corresponding to independent data showing a transduction efficiency of
80% on a per cell basis as determined with a GFP reporter gene
(Albrecht B, Fisch P, unpublished observations). A second band of 18 kd
was observed in untransduced and transduced DC. This band appeared to
represent a cellular protein with nonspecific binding of the anti-His
antibody and allowed us to compare the amount of lysate loaded onto
each lane. No changes in viability and immunophenotype of transduced DC
were detected for at least 3 days.

View larger version (38K):
[in this window]
[in a new window]
| Fig 3.
Expression of recombinant idiotype in SFV-transduced DC.
Lymphoma-derived immunoglobulin genes were inserted with an attached
hexahistidine tag into the SFV vector plasmid pSFV1. In vitro
transcripts were synthesized from idiotype SFV vector plasmids, and the
helper plasmid pSFVhelper1. BHK-21 packaging cells were electroporated
with a mixture of helper and idiotype vector transcripts. Twenty-four
hours later, infectious BHK-21 supernatants were harvested and used for
transduction of terminally differentiated DC at 1:1, 1:10, and 1:100
dilutions. Twenty-four hours after transduction, DC were lysed and
analyzed by Western blot with an antihistidine antibody. Bound antibody
was detected by chemiluminescence. rec Fab, recombinant Fab fragment
loaded as control; SFV/Fd, SFV/IgL, transduction with SFV vectors
encoding the heavy- or light-chain idiotype of the respective
patient's lymphoma; SM, 10- to 250-kd molecular weight marker.
|
|
Induction of idiotype-specific CTL with idiotype-presenting DC
CD8+ cells were obtained from the peripheral blood of
both patients with lymphoma during clinical remission. All other major cell types were depleted with monoclonal antibodies. As confirmed by
FACS analysis, more than 85% of the recovered population stained positive for CD3 and CD8. These cells were stimulated in the presence of IL-12 and IL-6, with autologous DC loaded with recombinant Fab
fragment derived from lymphoma cells of the respective patient. Alternatively, DC transduced with either the Fd or the IgL idiotype segment were also used for T-cell stimulation. T cells were
restimulated in the presence of IL-2 and IL-7 with freshly prepared DC,
presenting the same antigen as during the initial stimulation at weekly
intervals. Vigorous cell proliferation with a 2- to 3-fold expansion
per week was observed in wells with Fab-loaded DC. The cell
proliferation rate in wells with idiotype-transduced DC was
approximately half the growth rate achieved with Fab-loaded DC.
One week after the third restimulation, stimulated T cells were tested
for idiotype-specific cytotoxicity. Because the entire stimulation
protocol was designed to be feasible without the necessity of viable
autologous lymphoma cells, autologous LCL of both patients served as
surrogate target cells. These target cells were transfected with pCEP
vectors, and they stably expressed IgL or Fd molecules cloned from
autologous lymphoma cells. Idiotype expression by transfected LCL
was confirmed with the same anti-His-tag Western blot used to
analyze idiotype-expressing DC (Figure
4).

View larger version (41K):
[in this window]
[in a new window]
| Fig 4.
Expression of recombinant idiotype in stably transfected
LCL.
Lymphoma-derived immunoglobulin genes were inserted with an attached
hexahistidine tag into the EBV-replicon vector pCEP4.
Well-proliferating LCL were electroporated and selected with
hygromycin. Hygromycin-resistant LCL were lysed and analyzed by Western
blot with an antihistidine antibody. Bound antibody was detected by
chemiluminescence. rec Fab, recombinant Fab fragment loaded as control;
Fd1, IgL1, LCL transfected with pCEP4 vectors encoding the heavy- and
light-chain idiotype gene of patient 1; Fd2, IgL2, LCL transfected with
pCEP4 vectors encoding the heavy- and light-chain idiotype gene of
patient 2; SM, 10- to 250-kd molecular weight marker.
|
|
Specific lysis of cells expressing the idiotype derived from each
patient's lymphoma cells was demonstrated using
51Cr-labeled autologous, idiotype-transfected LCL as target
cells. Autologous LCL expressing the other patient's idiotype chains served as controls. These 51Cr release assays were
performed as cold target inhibition assays with an excess of the
typical NK target cell line K562.
T cells of patient 1 exhibited strong specific cytotoxicity (49% of
maximum release) against autologous Fd-expressing LCL after stimulation
with Fab-loaded DC (Figure 5). Weak lytic
activity (12% release) of the same T-cell population was detected
against IgL-expressing LCL. In contrast, lytic activity for autologous IgH idiotype was marginal (9% release) after stimulation with appropriately transduced DC and practically absent for IgL (5% release). Moderate NK activity was detected when K562 were used as
target cells (41% and 35%, respectively), whereas T cells stimulated with Fab-loaded DC had no detectable NK activity (less than 7% release). The experiment was confirmed with virtually identical results
after a fourth restimulation with idiotype-presenting DC (Figure 5).

View larger version (21K):
[in this window]
[in a new window]
| Fig 5.
Cytotoxicity of PBMC of patient 1 against
idiotype-expressing autologous LCL after stimulation with
idiotype-presenting autologous DC.
CD8+ PBMC of patient 1 were stimulated repetitively with
autologous DC loaded or transduced with idiotype derived from the
patient's lymphoma cells. Cytotoxic activity was assessed in a
standard 51Cr release assay with idiotype-expressing
autologous LCL or the NK target cell line K562 as target cells. An
excess of unlabeled K562 cells was added to LCL target cells to inhibit
NK activity. : DC loaded with recombinant Fab fragment derived from
the patient's lymphoma; and : DC transduced with SFV vectors
encoding autologous lymphoma-derived immunoglobulin heavy or light
chain; LCL/Fd1, LCL/IgL1, LCL of patient 1 stably transfected with
vectors encoding the idiotype heavy or light chain of the lymphoma of
patient 1; LCL/Fd2, LCL/IgL2, LCL of patient 1 stably transfected with
vectors encoding the idiotype heavy or light chain of the lymphoma of
patient 2.
|
|
Equivalent results with respect to autologous IgH-idiotype-specific
lysis and NK activity were obtained with DC-stimulated T cells from
patient 2 (Figure 6). The main difference
with respect to the antigens between both patients was found for
IgL-idiotype-expressing target cells: T cells of patient 2 killed
IgL-expressing LCL almost as efficiently as Fd-expressing target cells
(38% and 50% release, respectively).

View larger version (13K):
[in this window]
[in a new window]
| Fig 6.
Cytotoxicity of PBMC of patient 2 against
idiotype-expressing autologous LCL after stimulation with
idiotype-presenting autologous DC.
CD8+ PBMC of patient 2 were stimulated repetitively with
autologous DC loaded or transduced with idiotype derived from the
patient's lymphoma cells. Cytotoxic activity was assessed in a
standard 51Cr release assay with idiotype-expressing
autologous LCL or the NK target cell line K562. An excess of unlabeled
K562 cells was added to LCL target cells to inhibit NK activity. :
DC loaded with recombinant Fab fragment derived from the patient's
lymphoma; and : DC transduced with SFV vectors encoding
autologous lymphoma-derived immunoglobulin heavy or light chain;
LCL/Fd1, LCL/IgL1, LCL of patient 2 stably transfected with vectors
encoding the idiotype heavy or light chain of the lymphoma of patient
1; LCL/Fd2, LCL/IgL2, LCL of patient 2 stably transfected with vectors
encoding the idiotype heavy or light chain of the lymphoma of patient
2.
|
|
To gain a better estimate of the overall degree of idiotype-specific
lysis, allogeneic T cells from a voluntary donor were stimulated
simultaneously by the untransfected LCL of both patients. Lysis of LCL
by these allogeneic responder cells was measured in the same
experiments in which idiotype-specific lysis was determined, and it
amounted to 74% to 78% (data not shown). Therefore, this allogeneic
response was only moderately stronger that the specific lysis of
autologous idiotype-expressing LCL.
Characterization of idiotype-specific CTL
The composition of the effector cell populations was assessed by
flow cytometry (Table 3). A high percentage
of cells had phenotypic features of activated T cells with coexpression
of CD3 and HLA-DR. As expected for cultures initiated with a highly enriched CD8+ population, most cells (56%-93%) expressed
CD8 independent of the stimulation conditions. Notable differences,
however, were observed in the remaining cells. Corresponding to the NK
activity, a sizable fraction of cells in cultures stimulated with
SFV-transduced DC expressed the NK marker CD56 or CD16 (25%-44%). In
contrast, these markers were expressed only by a minority of
cells (4%-7%) after stimulation with protein-pulsed DC. Another
striking and unexpected difference existed with regard to the numbers
of CD4+CD8+ double-positive T cells. Only
cultures obtained with Fab-loaded DC contained a significant proportion
of effector cells expressing both CD4 and CD8 (22-27%).
To determine the nature of the T cell-target cell interaction in T
cells stimulated with Fab-loaded DC, specific lysis was measured after
the blockade of T-cell coreceptors and MHC molecules with monoclonal
antibodies (Figure 7). These experiments
were performed without the addition of cold K562 target cells.
Idiotype-specific lysis could be reduced from more than 50% to 18%
with an antibody directed against CD8 and to less than 5% with CD3-or
MHC I-specific antibodies. Anti-MHC II and anti-CD4 antibodies had
negligible effects on idiotype-specific lysis. The overall pattern of
killing served as an additional confirmation of the idiotype-specific lysis shown in Figures 5 and 6.

View larger version (34K):
[in this window]
[in a new window]
| Fig 7.
Inhibition of idiotype-specific cytotoxicity with
specific antibodies.
Autologous DC were repetitively stimulated against the idiotype of
autologous lymphoma cells with Fab-loaded dendritic cells. Specific
cytotoxicity was assessed in a standard 51Cr release assay
with idiotype heavy or light chain expressing autologous LCL as target
cells. For the inhibition of lytic activity, effector cells were
preincubated with anti-CD3, anti-CD4, or anti-CD8 antibody, and target
cells were preincubated with anti-MHC class I or anti-MHC class II
antibodies. AlloLCL, allogeneic LCL included as a negative control
target.
|
|
A computerized search for HLA class I-binding motives within the
idiotype sequences of both patients32 merely yielded the following peptides: NQFSLKLSSV (HLA-A 0201, Patient 1, heavy chain, FR3), KLLIYAAST (HLA-A 0201, Patient 1, light chain, FR2-CDR2), and
IVLRQSPATL (HLA-A 0205, Patient 2, light chain, FR1). These peptides,
however, had low disassociation scores below 100.
 |
Discussion |
The results of our experiments defined a standardized and highly
efficient protocol for the induction of anti-idiotype cytotoxic T cells
from patients with lymphoma. In daily clinical practice, an autologous
lymphoma cell line may not be available for most patients with
malignant lymphoma. We therefore developed a method based on frozen
biopsies and blood samples only. The protocol relies on a convenient
and rapid expression system for the immunoglobulin transcripts of
frozen lymphoma biopsies.27 The lymphoma-derived idiotype
genes were used to compare 2 distinct ways to present antigens to T
cells by dendritic cells uptake, processing, and presentation of
soluble protein antigen by DC and expression of the idiotype antigen
within the dendritic cells themselves by transduction with a viral
vector system.
To obtain a sufficient quantity of idiotype protein antigen from each
patient, recombinant, functionally folded lymphoma-derived Fab
fragments were generated by a periplasmic expression system in E. coli and purified with 1-step affinity
chromatography.27 With this strategy, idiotype protein
could be produced routinely within a period of 2 to 3 weeks after a
biopsy was performed. The relatively short production time and the
purity of the recombinant material (Figure 1) offer a valuable
alternative to other idiotype production methods, such as somatic cell
fusion of lymphoma cells with a heterohybrid cell line or production of
scFv fragments in plant cells.33,34 As
expected,3,4 monocyte-derived LC efficiently endocytosed
the recombinant idiotype Fab fragment.
For the endogenous antigen presentation strategy, the SFV vector system
allowed the efficient transduction of DC with idiotype genes and did
not lead to appreciable changes in DC viability or morphology for
several days. When compared to stable transfection of LCL cell lines
with cytomegalovirus promoter-driven idiotype genes, only 10% of
SFV-transduced DC were necessary to obtain specific bands of similar
intensity in Western blot analyses (Figure 3, 4). Even at a 1:100
dilution, infectious SFV supernatants gave rise to easily detectable
recombinant protein. According to these analyses, efficient
presentation of the idiotype antigen in the following T-cell
stimulation experiments could be assumed for both techniques used in
this study exogenous idiotype loading and endogenous idiotype expression.
Presentation of exogenous idiotype to autologous T cells by DC induced
strong cytotoxic activity against the heavy immunoglobulin chain of the
lymphoma cells in both patients. These patients were chosen on the
basis of the IgM isotype of their lymphoma B-cell receptor and
because of the availability of fresh blood samples at regular
intervals, but they represented otherwise unselected patients. The
overall level of specific lysis reproducibly approached an order of
magnitude not much lower than lysis in an allogeneic reaction performed
simultaneously within the same experiment.
Specific lysis could be detected against the idiotype light chain, but
the level of recognition was much higher in patient 2 than in patient
1. Nevertheless, this finding proved that immunoglobulin light chains
can also harbor lymphoma-specific antigens. Idiotype vaccines composed
of both immunoglobulin variable regions may thus be superior to single
CDR III-derived peptides for anti-idiotype vaccination.35
All specific cytotoxic activity in these experiments could be inhibited
by antibodies against the T-cell receptor, the CD8 coreceptor, and the
MHC class I molecules. Therefore, the main effector cells were classic
cytotoxic CD8+ T cells that recognized their antigens in an
HLA class I-restricted fashion.
Background lysis levels against autologous target cells transfected
with idiotype genes of the other patient proved that the target antigen
indeed resides in the variable immunoglobulin region of the lymphoma.
Neither constant regions nor the variable regions of the other
patient's lymphoma or of the polyclonal receptors constitutively
expressed by the LCL target cells were recognized. The cytotoxic
response was highly specific; even strongly immunogenic EBV-derived
antigens expressed by LCL cells did not raise the 51Cr
release above background.
Since the initial report of idiotype-specific CTL in a patient with
follicular lymphoma,18 lymphoma-specific T cells have been
described in various studies. In the human system, there is compelling
though indirect evidence that the critical antigen recognized by CTL is
indeed the idiotype of the lymphoma cells. Proliferative responses of T
cells in response to CDR III peptides have been observed after
anti-idiotype vaccination.13,21,22,35 Lymphoma-specific CTL
could be expanded in vitro by stimulation with CD40 ligand-activated
lymphoma cells, but the target antigen was not formally
identified.19 The detection of lymphoma-specific T cells in
patients after vaccination with idiotype protein strongly suggests, but
does not prove, idiotype-specific cytotoxicity.13,20 In
addition, idiotype-specific T cells secreting -interferon, a feature
characteristic of CTL responses, could be detected after idiotype
protein vaccination.22 Because our study relied on heterologous idiotype expression by transfected target cells, the
results unequivocally demonstrated that the tumor-specific antigen
recognized by CTL was indeed the lymphoma idiotype.
Despite efficient immunization with SFV vectors in experimental systems
in vivo,36 no idiotype-specific cytotoxicity could be
induced by idiotype SFV-transduced DC. A toxic or immunosuppressive effect of transduction with SFV in vitro appears unlikely because the
transduced DC remained essentially intact, proliferation of T cells
after stimulation with SFV-transduced DC occurred, and NK activity
could be demonstrated. Thus, endogenous expression of idiotype appears
to be less efficient than processing of endocytosed protein antigen for
the induction of MHC class I-restricted lysis. Consistent with findings
in experimental systems with well-defined antigens,37-39
our results suggest an additional requirement for MHC class
II-restricted presentation of exogenously acquired epitopes for the
induction of maximum idiotype-specific cytolytic activity. This may be
of special importance because the antigenicity of idiotypes of
individual patients is a priori unknown. When additional presentation
of idiotype epitopes by MHC class II complexes is absent, it appears
that the recently recognized potential of DC for direct activation of
NK cells40 overrides the stimulation of idiotype-specific CTL.
In the context of preferential stimulation of MHC class I-restricted
CTL, the emergence of a distinct CD4/CD8 double-positive T-cell
population after stimulation with protein-loaded DC may play a role.
Little information is available about the function of peripheral T
cells with this phenotype, but a critical helper function could be
possible in our experimental setting.
Understanding the requirements for optimal induction of
idiotype-specific cytotoxic T cells may help to design improved
vaccination strategies for B-cell lymphoma. Our data suggest that the
transfection of DC may not be the most efficient vaccination strategy,
and therefore presentation of the protein idiotype by activated
dendritic cells should be sought. Moreover, our data defined a
GMP-compatible protocol for the generation of idiotype-specific CTL for
adoptive transfer. Starting from 10 microtiter plates, the high
proliferation rate of stimulated T cells should permit the generation
of up to 109 idiotype-specific CTL. The transfer of
lymphoma-specific effector cells may be especially valuable after
allogeneic stem cell transplantation because donor lymphocyte infusion
(DLI) can have dramatic therapeutic efficacy for patients with relapsed
lymphoid malignancy.41 To avoid the potentially deleterious
effects of DLI-associated graft-versus-host disease, the adoptive
transfer of idiotype-specific immunity after immunization of the donor
has been proposed.42,43 Active donor immunization, however,
may not be possible for unrelated donors. For unrelated donors, a
standardized and broadly applicable protocol for in vitro stimulation
of idiotype-specific donor T cells by donor-derived DC against the
patient's idiotype may be especially valuable.
 |
Acknowledgments |
We thank Roland Mertelsmann for financial support and assignment of
laboratory space. We also thank Marie Follo for DNA sequence analysis,
Helmut Lang for performing HLA typing, and Ozan Alkan and Mathias
Ölke for helpful discussions.
 |
Footnotes |
Submitted July 22, 1999; accepted October 5, 1999.
Supported by Sonderforschungsbereich 364 of the Deutsche Forschungsgemeinschaft.
Reprints: Hendrik Veelken, Department of
Hematology/Oncology, Freiburg University Medical Center, Hugstetter
Strasse 55, D-79106 Freiburg, Germany; e-mail:
veelken{at}mm11.ukl.uni-freiburg.de.
The publication costs of this
article were defrayed in part by
page charge payment. Therefore,
and solely to indicate this fact,
this article is hereby marked
"advertisement"
in accordance with 18 U.S.C.
section 1734.
 |
References |
1.
Cella M, Sallusto F, Lanzavecchia A.
Origin, maturation and antigen presenting function of dendritic cells.
Curr Opin Immunol.
1997;9:10[Medline]
[Order article via Infotrieve].
2.
Banchereau J, Steinman RM.
Dendritic cells and the control of immunity.
Nature.
1998;392:245[Medline]
[Order article via Infotrieve].
3.
Sallusto F, Cella M, Danieli C, Lanzavecchia A.
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
J Exp Med.
1995;182:389[Abstract/Free Full Text].
4.
Lanzavecchia A.
Mechanisms of antigen uptake for presentation.
Curr Opin Immunol.
1998;8:348.
5.
Rock KL.
A new foreign policy: MHC class I molecules monitor the outside world.
Immunol Today.
1996;17:131[Medline]
[Order article via Infotrieve].
6.
Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P.
Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer.
Int J Cancer.
1998;77:538[Medline]
[Order article via Infotrieve].
7.
Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al.
Induction of antigen-specific T cell anergy: an early event in the course of tumor progression.
Proc Natl Acad Sci U S A.
1998;95:1178[Abstract/Free Full Text].
8.
Fields P, Fitch FW, Gajewski TF.
Control of T lymphocyte signal transduction through clonal anergy.
J Mol Med.
1996;74:673[Medline]
[Order article via Infotrieve].
9.
Sallusto F, Lanzavecchia A.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha.
J Exp Med.
1994;179:1109[Abstract/Free Full Text].
10.
Herbst B, Köhler G, Mackensen A, Veelken H, Mertelsmann R, Lindemann A.
CD34+ peripheral blood progenitor cell- and monocyte-derived dendritic cells: a comparative analysis.
Br J Haematol.
1997;99:490[Medline]
[Order article via Infotrieve]. |